Search over 3,000 reports

    Acalabrutinib - Launch Insight, 2017

    Acalabrutinib - Launch Insight, 2017
    Date: Jan, 2018
    Type: Pharmaceutical Industry Report
    Pages: 50
    Geography: Global
    Delivery Timeline: 48 hours
    SKU: DILI0017
    "Acalabrutinib - Launch Insight, 2018" report by DelveInsight provides comprehensive insights about Acalabrutinib 's launch. The report covers all indications for which Acalabrutinib is being developed and also provides its competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.

    Acalabrutinib Post-Launch Market Positioning Scenario
    The report will provide a clear picture of market positioning of the upcoming launch of Acalabrutinib and will also provide the insight about how Acalabrutinib will evolve in the market as well as within its respective class. Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.

    Acalabrutinib Attributes Analysis
    Attributes analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsightÂ’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    • Detailed product description including its chemical properties, molecule type and mechanism of action
    • Detailed description of non-clinical and clinical studies for all the indications
    • Patent expiry analysis of the drug along with other competitors in the market
    • Forecasted sales till 2022
    • Acalabrutinib market positioning analysis
    • Acalabrutinib class share evolution

    Reasons to Buy
    • Establish a comprehensive understanding of the emerging product, Acalabrutinib
    • Understand Acalabrutinib `s therapeutic performance through pre-clinical and clinical characterization in its associated indications
    • Identify the upcoming launch timeline of Acalabrutinib
    • Plan effective competitive strategy by understanding Acalabrutinib `s market positioning post-launch and its in-class market evolution
    • Plan counter-effective strategies around Acalabrutinib `s patents expiry details
    • Understand and analyze post launch growth prospects of Acalabrutinib through its forecasted sales
    • Identify Acalabrutinib `s attributes and use it for target finding, drug repurposing, and precision medicine
    • Identify the competitors in the same space as Acalabrutinib
    1. Report Introduction
    2. Acalabrutinib Overview
    3. Acalabrutinib : Mechanism of action
    4. Pre-clinical Characterization
    • Indication 1
    • Indication 2
    5. Clinical Characterization
    • Indication 1
    • Indication 2
    6. Product Developmental Activities
    • Collaboration
    • Mergers & Acquisitions
    • Financing
    7. Acalabrutinib Market Evolution
    8. Acalabrutinib Class Share Evolution
    9. Acalabrutinib Market Positioning
    10. Patent Expiry Analysis
    11. Competitive Landscape for Acalabrutinib in major indications
    Appendix
    Methodology
    Consulting Services
    About DelveInsight
    Contact Us
    Note: Certain sections of the table of contents would vary according to the availability of information
    Table 1: Acalabrutinib , Heat Map
    Table 2: Clinical Trial Landscape
    Table 3: Clinical Efficacy Data from Cross Trials
    Table 4: Competitive Landscape for Acalabrutinib in Indication 1
    Table 5: Competitive Landscape for Acalabrutinib in Indication 2
    Figure 1: Acalabrutinib Developmental Milestones
    Figure 2: Acalabrutinib Sales Forecast till 2022
    Figure 3: Acalabrutinib Class Share Evolution
    Figure 4: Comparative Analysis of Acalabrutinib with Marketed Products in the same class
    Figure 5: Patent Expiry Analysis
    Acalabrutinib

    ACP-196

    AstraZeneca Zeneca

    B-cell malignancy

    Chronic Lymphocytic Leukaemia

    Mantle Cell Lymphoma
    • Single User License
      (20% Off)
      $1,500.00
    • Site License
      (30% Off)
      $3,000.00
    • Global License
      (40% Off)
      $4,500.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap